Alkeus Pharmaceuticals Announces Positive Gildeuretinol Data Will Be Presented During the 12th International FLORetina ICOOR Congress December 5–8 in Florence, Italy
CAMBRIDGE, Mass., December 5, 2024 – Alkeus Pharmaceuticals, Inc. today announced that results from its clinical studies of investigational oral gildeuretinol for the treatment of Stargardt disease (TEASE) will be presented at the 12th International FLORetina ICOOR Congress being held December 5-8 in Florence, Italy.
Learn More